The term myxosarcoma is currently not used in standard classification for soft tissue tumors, but restricted to cardiac tumors. Primary cardiac myxosarcoma is a very rare disease and is difficult to differentiate from myxoma clinically and pathologically. We report a case of left atrial myxosarcoma with widespread systemic metastasis in a 21-yr-old male. The patient presented with sudden onset of intermittent dyspnea and orthopnea. Echocardiography showed a mobile, pedunculated tumor, 7.5x5x2 cm in size, at left atrium. Histologically, the excised tumor showed an amorphous finely fibrillar and mucinous stroma, in which irregular cords and clusters of lepidic cells and large stellate cells with plump vesicular nuclei resembled the usual type of cardiac myxoma were noted. And it showed focally cellular area with great nuclear pleomorphism and frequent mitoses. The patient received combination chemotherapy, peripheral blood stem cell collection transplantation and operations for systemic metastases in the brain, skeletal muscle and lung. He is alive at present 37 months after initial diagnosis and has no more new metastatic lesion.
Adult ; Case Report ; Heart Neoplasms/therapy ; Heart Neoplasms/pathology* ; Human ; Male ; Myxosarcoma/therapy ; Myxosarcoma/secondary* ; Myxosarcoma/pathology*

Repetitive low dose thioacetamide (TA) treatment of hepatocytes was found to induce cells in G2 arrest. In the present study, an attempt was made to investigate alterations in expression of cell cycle regulators after G1 progression in the same repetitive low dose TA treated hepatocytes system and to define the determinators involved in G2 arrest. TA was daily administered intraperitoneally, with a dose of 50 mg/kg for 7 days. Expression levels of cyclin E and CDK2 were similar, increased at day 1 and reached a peak at day 2. And they recycled from day 3 reaching a second peak at day 5. Expression level of cyclin A was similar to p27(Kip1) and p57(Kip2) but not to CDK2 and increased to a peak level at day 2. Expression levels of cyclin B1 and cdc2 were similar although the cyclin B1 level was generally low, decreased from day 1 to basal levels at day 3 and persisted at a low level till day 7. The expression level of cyclin G1 was similar to p53 that peaked at day 3 and again at day 6 elevated over basal level. BrdU-labeled hepatocytic nuclei increased from 12 h, reached a peak at day 2, then decreased, and were not detectable from day 6. The number of PCNA-labeled nuclei increased immediately, peaked at day 2, and maintained till day 7. These results suggest that G2 arrest induced by repeated TA treatment might be p53-dependent, via activation of cyclin G1, rather than inhibition of cyclin B1- cdc2 complex, and inhibitors holding S phase progression might be p27(Kip1) and p57(Kip2).
Animals ; Bromodeoxyuridine/metabolism ; CDC2 Protein Kinase/drug effects/metabolism ; *CDC2-CDC28 Kinases ; Cell Cycle/drug effects/*physiology ; Cell Cycle Proteins/drug effects/metabolism ; Cyclin-Dependent Kinases/antagonists & inhibitors/drug effects/metabolism ; Cyclins/drug effects/metabolism ; Dose-Response Relationship, Drug ; G1 Phase/drug effects/*physiology ; Liver/*drug effects/pathology ; Male ; Nuclear Proteins/drug effects/metabolism ; Proliferating Cell Nuclear Antigen/metabolism ; Protein p53/metabolism ; Protein-Serine-Threonine Kinases/antagonists & inhibitors/drug effects/metabolism ; Rats ; Rats, Sprague-Dawley ; Thioacetamide/administration & dosage/*pharmacology ; Tumor Suppressor Proteins/drug effects/metabolism